<DOC>
	<DOCNO>NCT00003906</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use raloxifene tamoxifen may fight breast cancer block uptake estrogen tumor cell . PURPOSE : Randomized double-blinded clinical trial compare effectiveness raloxifene tamoxifen prevent breast cancer postmenopausal woman .</brief_summary>
	<brief_title>Study Tamoxifen Raloxifene ( STAR ) Prevention Breast Cancer Postmenopausal Women</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether raloxifene less effective tamoxifen significantly reduce incidence rate invasive breast cancer postmenopausal woman . - Evaluate effect tamoxifen raloxifene incidence intraductal carcinoma situ , lobular carcinoma situ , endometrial cancer , ischemic heart disease , fracture hip spine , Colles ' fracture wrist participant . - Evaluate toxic effect regimens participant . - Determine effect regimens quality life participant ( select center ) . ( Quality life evaluation close accrual effective 5/31/01 . ) OUTLINE : This randomize , double-blind study . Participants stratify age ( 35 49 v 50 59 v 59 ) , race ( black v white v ) , history lobular carcinoma situ ( yes v ) , prior hysterectomy ( yes v ) , estimate absolute risk invasive breast cancer within 5 year ( use Gail model ) ( le 2.0 vs 2.0-2.9 v 3.0-4.9 v 5.0 great ) . Participants randomize 1 2 arm . - Arm I : Participants receive oral tamoxifen plus placebo daily 5 year . - Arm II : Participants receive oral raloxifene plus placebo daily 5 year . Quality life assess ( select center ) baseline 6 , 12 , 18 , 24 , 30 , 36 , 42 , 48 , 54 , 60 , 72 month . ( Quality life evaluation close accrual effective 5/31/01 . ) Participants follow annually 5 year . PROJECTED ACCRUAL : Approximately 19,000 participant accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Postmenopausal woman increase risk develop invasive breast cancer , meet one follow criterion : At least 12 month since spontaneous menstrual bleeding Prior document hysterectomy bilateral salpingooophorectomy At least 55 year age prior hysterectomy without oophorectomy Age 35 54 prior hysterectomy without oophorectomy OR status ovary unknown document folliclestimulating hormone level demonstrate elevation postmenopausal range Histologically confirm lobular carcinoma situ treat local excision OR minimum project 5 year probability invasive breast cancer least 1.66 % , use Breast Cancer Risk Assessment Profile No clinical evidence malignancy physical exam within past 180 day No evidence suspicious malignant disease bilateral mammogram within past year No bilateral unilateral prophylactic mastectomy No prior invasive breast cancer intraductal carcinoma situ Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 35 Sex : Female Menopausal status : See Disease Characteristics Performance status : No restrict normal activity significant portion day Life expectancy : At least 10 year Hematopoietic : Granulocyte count least 1,500/mm^3 Complete blood count differential normal Platelet count normal Hepatic : SGOT SGPT normal Bilirubin normal Alkaline phosphatase normal Renal : Creatinine normal Cardiovascular : No cerebral vascular accident , transient ischemic attack , atrial fibrillation , uncontrolled hypertension No deep vein thrombosis Pulmonary : No pulmonary embolus Other : No prior malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No concurrent nonmalignant disease would preclude administration tamoxifen raloxifene No clinical depression , psychiatric condition , addictive disorder No uncontrolled diabetes PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 3 month since prior estrogen progesterone replacement therapy , oral contraceptive , androgen , luteinizing hormonereleasing hormone analog , prolactin inhibitor , antiandrogens At least 3 month since prior tamoxifen , raloxifene , selective estrogenreceptor modulators less 3 month duration Concurrent Estring allow Radiotherapy : No prior breast radiotherapy Surgery : See Disease Characteristics Other : No prior systemic adjuvant therapy breast cancer No participation cancer prevention osteoporosis prevention study involve pharmacologic intervention ( ) NSABPP1 patient receive placebo eligible No concurrent warfarin cholestyramine Concurrent calcitonin nonhormonal medication ( e.g. , cholecalciferol , fluoride , bisphosphonates ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>breast cancer</keyword>
</DOC>